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Background: Toxoplasma gondii is an obligate intracellular parasite that causes a pathological status known as
toxoplasmosis, which has a huge impact on human and animal health. Currently, the main control strategy
depends on the usage of drugs that target the acute stage of the infection, however, drawbacks were encountered
while applying this method; therefore, development of an alternative effective method would be important
progress. Deoxyribose Phosphate Aldolase (TgDPA) plays an important role supporting cell invasion and providing
energy for the parasite.
Methods: TgDPA was expressed in Escherichia coli and the purified recombinant protein was used to immunize
rats. The antibodies obtained were used to verify in vitro expression of TgDPA. The vector pVAX1 was utilized to
formulate a DNA vaccine designated as pTgDPA, which was used to evaluate the immunological changes and the
level of protection against challenge with the virulent RH strain of T. gondii.
Results: DNA vaccine, TgDPA revealed that it can induce a strong humoral as well as cellular mediated response
in mice. These responses were a contribution of TH1, TH2 and TH17 type of responses. Following challenge, mice
immunized with TgDPA showed longer survival rates than did those in control groups.
Conclusions: Further investigation regarding TgDPA is required to shed more light on its immunogenicity and its
possible selection as a vaccine candidate.
Keywords: Toxoplasma gondii, Deoxyribose phosphate aldolase, DNA vaccinesBackground
Toxoplasma gondii is an important zoonotic parasite
infecting a wide range of warm blooded hosts, causing a
pathological condition known as toxoplasmosis [1]. The
infection is mainly acquired either by using water con-
taminated with oocysts released by the final host or
handling intermediate host tissues infested with the
asexual cysts [2,3]. In humans, there are two types of the
infection according to symptoms; the first type is the
asymptomatic form, resulting in a latent infection with
tissue cysts. This form is less frequently seen in immuno-
logically intact individuals. However, the infection could* Correspondence: lixiangrui@njau.edu.cn
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unless otherwise stated.be severe in specific groups of patients, such as immuno-
logically impaired individuals (AIDS or organ transplants)
or congenitally infected fetuses and newborns [4,5].
Currently, the strategies of toxoplasmosis control
mainly rely on the application of chemotherapeutics tar-
geting the acute phase of the infection, however, some
drawbacks were found to be associated with drug applica-
tion, e.g; rapid re-infection besides toxic effects of the
drugs [6,7]. Such issues ‘blew the whistle’, shifting the
research directions into the area of vaccine development
as an alternative control strategy for toxoplasmosis, with
DNA vaccines receiving considerable attention [6].
Recent important progress has been made identifying
anti-toxoplasma vaccine candidates that can stimulate an
immunological response, with most of the work focusingLtd. This is an Open Access article distributed under the terms of the Creative
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SAG3, and SAG1 was recognized to be the most pro-
mising candidate in this group [8-11]. In the same context,
T. gondii excretory secretory antigens like GRA molecules,
have also been reported to demonstrate significant im-
munogenic capabilities [12-14]. Vaccination with DNA
vaccines has been found to induce effective humoral and
cellular immune responses, with both CD4+ T helper cells
and CD8+ cytotoxic T cells included in these responses
[15]. Such elements are important for understanding the
mechanisms through which the parasite modulates the
host immune response during both acute and chronic
phases of the disease [16].
Deoxyribose phosphate aldolase, a glycolytic enzyme,
functionally mediates in host cell invasion, acting as a
bridge linking actin filaments to the parasite’s surface
adhesion microneme protein 2. Furthermore, aldolase
plays an essential role providing carbon and energy
sources for the organism, as part of the glycolysis cycle,
on which the parasite gliding motility depends during
the invasion process [17-20].
Blocking the parasite from invading the cell and con-
sequently preventing the parasite form multiplying may
help in reducing the parasitic burden and leave the para-
site exposed to other immunological elements, thus in
this study we demonstrated the immunological changes
after vaccination of mice with a DNA vaccine encoding




Six to eight week-old female Swiss Webster (SW)
mice were purchased from The Center of Comparative
Medicine, Yangzhou University (Yangzhou, China) and
maintained under specific-pathogen-free standard condi-
tions. All animal experiments were approved by the Animal
Ethics Committee of Nanjing Agricultural University
(Approval number 200709005). Toxoplasma gondii strain
RH (Type I), was provided by The Laboratory of Veterinary
Molecular and Immunological Parasitology, Nanjing
Agricultural University, China. To maintain the parasite,
as described by [21], intraperitoneally injected SW mice
were infected with the parasite tachyzoites. Every
3 days, the tachyzoites were harvested and recovered
from peritoneal washings of infected mice to be used
for re-infection.
Construction of the prokaryotic plasmid
According to the manufacturer's protocol Trizol re-
agent (Takara, Life Technologies), total RNA of T. gondii
was extracted from T. gondii tachyzoites, followed by
construction of the cDNA. The open reading frame
(ORF) of Deoxyribose Phosphate Aldolase (TgDPA) gene(XM_002365690.1) was obtained from T. gondii cDNA by
PCR amplification using the following synthetic primers
in which recognition sites were inserted as underlined
below.
DPA: Forward primer: 5’- TGGATCCATGGATGCAG
AACAACAGG-3’ (BamH I).
Reverse primer: 5’- GCAAGCTTTTACAGAACGAAT
TCCCGG-3’ (Hind III).
The PCR product of TgDPA was inserted into the
pMD-18 T Vector (TaKaRa) to generate prokaryotic
plasmid pMD-TgDPA. The recombinant plasmid was
used to transform the bacteria E. coli DH5α (JM109).
Insertion was confirmed by sequencing in both direc-
tions. After purification, pMD-TgDPA recombinant plas-
mid was double digested with appropriate restriction
enzymes (BamH I/Hind III) and sub-cloned into the
matching sites of pET28a (+) vector (Novagen). Follow-
ing the screening by enzymatic cleavage, the positive
clones were sequenced in both directions to ensure the
plasmid designated as pET28a/TgDPA was successfully
constructed.
Expression and purification of TgDPA recombinant protein
The recombinant plasmid designated as pET28a/TgDPA
was used to transform E. coli bacteria strain BL21
(DE3), and protein expression was induced by addition of
0.8 mM Isopropyl-β-D-thiogalactopyranoside (IPTG) after
the OD600 of the bacterial culture reached 0.6 at 37°C.
The cells were incubated at 37°C for 5 hr and harvested
by centrifugation. The cell pellet was lysed using lysozyme
(10 μg/ml) followed by disruption of the cells using
sonication. Expression of the protein was analyzed by
12% (w/v) Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS-PAGE).
The recombinant protein was purified by Ni2+-nitrilo-
triacetic acid (Ni2+-NTA) column (GE Healthcare) ac-
cording to the manufacturer’s instructions. Purity of the
protein was detected by 12%SDS-PAGE. The concentra-
tion of the protein was determined according to the
Bradford procedure using bovine serum albumin (BSA)
as a standard. The purified protein was used to develop
anti-rTgDPA sera and the rest of the protein was stored
at −20°C for later applications.
Construction of the eukaryotic plasmid
The restriction enzymes BamH I and Xho I were used to
digest the recombinant plasmid pET28a/TgDPA and the
target gene DNA fragment was directionally sub-cloned
into the pVAX1 vector (Invitrogen, Life Technologies),
which was previously linearized with similar enzymes.
The resultant recombinant plasmid designated pTgDPA
was verified and confirmed by sequencing in both direc-
tions and also with double enzyme digestion. Plasmids
were then purified from transformed E. coli DH5 (JM109)
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Plasmid mega Kit Qiagen) following the manufacturer’s
instructions, dissolved in sterile endotoxin-free H2O and
the concentration was determined by spectrophotometer
at OD260 and OD280. The recombinant plasmid was stored
at −20°C until use.
Plasmid in vitro translation of pTgDPA
BHK cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, GIBCO) with 10% Fetal Bovine Serum
(FBS), 100 mg/ml streptomycin and 100 IU/ml penicillin
at 37°C in the presence of 5% CO2. Before transfection,
BHK cells were transferred in a 6-well plate (Costar,
USA). When the confluency of the cells reached 80%-
90%, 5 μg of the recombinant eukaryotic plasmid (pTgDPA)
was used to transfect the cells using Lipofectamine 2000 re-
gent (Invitrogen) according to the manufacturer’s guidance.
The empty vector pVAX1 (5 μg) was also transfected into
BHK cells as a negative control. Lipofectamine 2000 re-
agent was respectively mixed with pTgDPA and pVAX1
at a concentration of 10 μg/ml in DMEM without Fetal
Bovine Serum (FBS) and antibiotics, and was incubated
at room temperature for 30 min. The mixture of lipofec-
tamine and plasmid was then added into BHK cells. The
cells were incubated with the transfection mix for 6 hr
at 37°C in the presence of 5% CO2. At the end of incu-
bation, fresh growing medium was supplemented and
plates were returned to the cell incubator for further incu-
bation. After 48 hr of incubation, BHK cells were collected
and expression of the gene was evaluated by Western blot-
ting analysis.
Mice immunization and challenge
To observe the immunogenicity of DPA, mice were
randomly divided into four groups (25/group). Before vac-
cination, plasmids were diluted and suspended in sterile
phosphate buffered saline (PBS pH 7.4) to a final con-
centration of 100 μg/ml. All experimental groups were
injected intramuscularly (quadriceps muscle), tw{Capron,
1988 #496}o times at weeks 0 and 2. Control groups re-
ceived PBS or empty plasmid or no treatment. Blood sam-
ples of mice were collected before vaccination (negative
control), as well as at the time of the second injection and
2 weeks after the second injection. The sera were stored
at −20°C for antibody evaluation and cytokine measure-
ment. Two weeks after the last injection, the mice in the
four groups were challenged intraperitoneally (i.p) with 2 ×
104 tachyzoites of T. gondii RH strain. The survival times of
the mice were observed and recorded on a daily basis.
Determination of antibodies and isotype distribution by
ELISA
Enzyme-linked immunosorbent assay, ELISA technique,
was used to determine the levels of total IgG in serasamples collected at week 0, 2 and 4, while levels of IgA,
IgM, IgE and subclasses IgG1 and IgG2a, were determined
in sera samples collected at week 4. The microtiter plates
(Costar, USA) were coated with 5 μg rTgDPA recombin-
ant protein in 50 mM carbonate buffer (pH 9.6) and incu-
bated at 4°C overnight. After three washes, the plates were
blocked with 2% skimmed milk for 1 h at 37°C and subse-
quently incubated with the mouse sera diluted (1:100) in
the same blocking buffer for 1 h at 37°C. HRP-conjugated
goat anti-mouse of IgA, IgM, IgE, IgG, IgG1 and IgG2a
(Santa Cruz Biotechnology) were used as secondary anti-
body (1:1000). Finally, the immune complexes were devel-
oped by incubating with 3,3,5,5-Tetramethylbenzidine
(TMB) for 30 min. The reaction was stopped by adding
2MH2SO4, and the absorbance was measured at 450nm
with an automated ELISA reader (MULTISKAN FC,
Thermo scientific), all samples were run in duplicate.
Assay of cytokines
To assay cytokine production levels, sera from each experi-
mental group were obtained as described previously. Inter-
feron Gamma (IFN-γ), Interleukin-4 (IL-4), Interleukin-17
(IL-17) and Transformation Growth Factor-β1 (TGF-β1)
were measured using ready ELISA kits according to
the manufacturer’s instructions (Boster Systems, Wuhan,
China). Cytokine concentrations were determined by ref-
erence to standard curves constructed with known
amounts of mouse recombinant IL-4, IL-17, IFN-γ and
TGF-β1. The analysis was performed with the data from
three independent experiments.
Flow cytometry analysis of T cell subsets and MHC
molecules
The percentages of T cells subsets CD4+ and CD8+, be-
side MHC-I and MHC-II molecules in the spleenocytes
of mice in the test groups, pTgDPA and pVAX1, PBS
and blank, were analyzed using the flow cytometry tech-
nique as described by [22].
Splenocytes suspensions (1 × 106 cells/ml) were dually
stained with anti-mouse CD3e-FITC + anti-mouse CD8-PE,
anti-mouse CD3e-FITC + anti-mouse CD4-PE, anti-mouse
CD3e-FITC + anti-mouse MHC-I-PE or anti-mouse CD3e-
FITC + anti- mouse MHC-II-PE (eBioscience) for 30 min at
room temperature in the dark. Cell population analysis was
conducted by FACScan flow cytometry with CellQuest soft-
ware (BD Biosciences, Franklin Lakes, NJ, USA). A lympho-
cyte specific gating was set according to forward and side
scatters profiles. The percentages of CD4+ and CD8+ T
lymphocytes, MHC-I and MHC-II molecules in mice splee-
nocytes were determined as described by [23].
Statistical analysis
All statistical analyses were performed by Graphpad Prism
5.Ink software. The differences of the data between all the
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of the mice was compared using the Kaplan-Meier me-
thod. The results in comparisons between groups were
considered different if P < 0.05.
Results
TgDPA recombinant plasmids expression
Following sequence analysis confirming that the TgDPA
DNA fragment was directionally inserted; pET28a/TgDPA
was successfully constructed (Figure 1A). Expression of
the recombinant protein took place by IPTG induction,
followed by purification, the product was analyzed using
SDS-PAGE (Figure 2A). The purified protein was used to
develop polyclonal antibodies (anti-rTgDPA) and west-
ern blotting technique was used to verify the results
(Figure 2B).
As for the eukaryotic plasmid pTgDPA, a separate trial
was conducted to screen in vitro expression. Lysates of
the BHK cells transfected with pTgDPA were probed with
anti-rTgDPA polyclonal antibodies revealing successful
expression of the protein (Figure 2C), while cells trans-
fected with empty pVAX1 exposed no specific bands and
remained negative (Figure 2D).
Antibody response in immunized mice and subclass
determination
The titers of total IgG, beside subclasses IgG1 and IgG2a
were measured prior to and after immunization, using
standard ELISA. As shown in Figure 3A, specific total
IgG antibodies were detected in the experimental groupFigure 1 Recombinant plasmids of TgDPA. (A) Lane (1) the prokaryotic
enzymes and the product was resolved by 1% agarose gel to verify a band
the eukaryotic construct pVAX1/TgDPA was double digested by BamH I an
verify a band of size 807 bp. (M) Represents DNA Molecular marker.vaccinated with pTgDPA. There was a significant dif-
ference at (p < 0.05) between pTgDPA group after first
immunization (0.651 ± 0.04) and 2nd immunization
(0.752 ± 0.03), compared to the control groups of pVAX1
(0.073 ± 0.011), PBS (0.050 ± 0.07) and Blank (0.07 ± 0.03).
IgG isotype determination revealed that, both IgG1
(1.33 ± 0.485) and IgG2a (0.506 ± 0.029) were significantly
(P < 0.05) stimulated after delivering the antigen (Figure 3B
and C). Moreover, the difference between the levels of
these isotypes was found to be significant at (P < 0.05), for
the advantage of IgG1 (Figure 3G). Regarding IgA, IgM
and IgE, and when compared to the control groups, dy-
namics of the first two antibody types demonstrated high
OD values (P < 0.05) in the immunized group (0.974 ±
0.33) and (1.55 ± 0.26) respectively (Figure 3D and E).
However, IgE activity showed no significant changes at the
time of evaluation (Figure 3 F).
Cytokine production
Sera samples collected at weeks 0, 2 and 4 were used to
measure the amounts of IFN-γ, IL-4, IL-17 and TGF-β1
produced in the different experimental groups. As shown
in Figure 4A, mice vaccinated with pTgDPA generated
significant levels of IFN-γ at (P < 0.05) compared to mice
in the control groups, peak production was reached
2 weeks after the last immunization (697.0 ± 8.39).
IL-4 and IL-17 of the pTgDPA group showed a sig-
nificant difference (P < 0.05) against the control groups
(Figure 4B and C). The peak of production was also at
2 weeks after the booster dose (91.6 ± 1.34) for IL-4 andconstruct pET28/TgDPA was double digested by Bam I and Hind III
of size 807 bp. (M) Represents DNA Molecular marker. (B) Lanes 1 & 2,
d Xho I enzymes and the product was resolved by 1% agarose gel to
Figure 2 Identification of TgDPA expression in E. coli BL21 (DE3) by SDS-PAGE and western-blotting. (A) Purified recombinant TgDPA
protein was resolved by 12% SDS-PAGE gel and stained with coomassie brilliant blue R250. (B) Western blot of rTgDPA recombinant product
probed with sera of rats experimentally immunized with rTgDPA. (C) Western blot of pVAX1/TgDPA expressed in BHK cells probed with anti-rTgDPA
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Figure 3 Specific antibody response induced by DNA immunization with pTgDPA compared to pVAX I, PBS and blank controls using
indirect ELISA. (A) Total IgG was evaluated in sera samples collected at 3 time points marked as week 0, week 2 and week 4 (n = 5). levels of:
(B) IgG1 (C) IgG2a, (D) IgA, (E) IgM and (F) IgE in sera samples collected at week 4 of the experiment (n = 5). (G) Comparison of the distribution
levels of IgG1 and IgG2a subclasses in sera of pTgDPA vaccinated group after the booster dose. In all experiments, comparison results were
expressed as means ± SD of OD450. The asterisk designates statistically significant differences (p < 0.05) between groups.








































































Figure 4 Cytokine production. Antibody-captured ELISA was used to determine the production levels of (A) IFN-γ, (B) IL-4, (C) IL-17 and (D)
TGF-β1, in sera samples (n = 5) collected at weeks 0, 2 and 4, and the comparison results were expressed as means ± SD of pg/ml. The asterisk
designates statistically significant differences (p < 0.05) between groups. Results presented here were from three independent experiments.
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displayed a different activity. Immunized groups showed a
significant peak after the first immunization (70.4 ± 6.66),
which was dramatically decreased (34.2 ± 2.26) two weeks
after the last immunization. Compared to the control
groups both time points were significant at (P < 0.05).
Recruitment of T lymphocytes subpopulations and MHC
molecules
As shown in (Figures 5A & 6A), following immunization
with pTgDPA, the percentage of CD4+ T cells was sig-
nificantly increased (P < 0.05) in the pTgDPA immunized
group at week 4 (22.74 ± 2.23), compared with that in
pVAX1 group (12.34 ± 1.90), PBS group (10.36 ± 1.46)
and the blank group (9.44 ± 1.33).
As for CD8+ T cells, significant differences (P < 0.05)
were also detected among the different experimental
groups at 2 weeks after the last immunization. TgDPA
group showed the highest percentage (6.47 ± 0.40), while
pVAX1, PBS and blank control group remained at low
levels as (2.13 ± 0.16), (3.04 ± 0.24) and (2.80 ± 0.17) re-
spectively (Figures 5B and 6B).
After both prime and booster immunizations, MHC-I
molecules of the immunized group displayed sustained
high significant readings (33.89 ± 1.83) and (32.22 ± 1.98)
in contrast to pVAX1 (18.04 ± 1.34), PBS (17.85 ± 1.98)
and Blank (17.56 ± 1.78) groups (Figures 5C & 6C). Con-
cerning MHC-II molecules, a gradually increasing pattern
was noticed in the vaccinated group (Figures 5D & 6D)
starting at week 2 of the experiment reaching a peak point(5.81 ± 0.87) at week 4. Compared to control groups
(1.85 ± 0.74), (1.74 ± 0.65) and (1.99 ± 0.82) the difference
between these values was found significant at (P < 0.05).
Protection of vaccinated mice against challenge with
T. gondii RH strain
In order to evaluate the protective effect of pTgDPA
DNA vaccine against acute toxoplasmosis, vaccinated
and control mice groups were challenged with lethal
T. gondii tachyzoites within the second week after
booster immunization. Mortality was observed daily until
all the mice died and survival curves of different groups
were generated and are shown in (Figure 7). Significantly
longer survival time (20 days) was observed in mice im-
munized with pTgDPA against the control group, who
died within 8–9 days after challenge (p < 0.05).
Discussion
In this study, we have demonstrated that a DNA vaccine
encoding DPA of T. gondii could elicit a considerable
specific immune response, as well as providing signifi-
cant levels of protection against T. gondii challenge.
In this report, humoral response was analyzed after vac-
cination with TgDPA. Immunized mice generated specific
high titers of IgG, in contrast to control groups. Analysis
of IgG isotypes revealed that the levels of IgG1 were sig-
nificantly higher than that of IgG2a. Similar results were
detected after T. gondii antigens like cathepsin proteases,
protein kinase 3 and GRA4 were evaluated [24-26]. IgG2a
and IgG1 are characteristic of TH1 and TH2 immunity,
Figure 6 Flow cytometry strategy. Detection of T lymphocyte subpopulation and MHC molecules using flow cytometry technique (CD3 gated),
(A) CD4+ T lymphocytes (CD3+CD4+, region Q2). (B) CD8+ T lymphocytes (CD3+CD8+, region Q2). (C) MHC-I molecules (CD3+MHC-I, region Q2).





































































Figure 5 Quantification of T lymphocytes and MHC molecules using flow cytometry analysis. Harvested at weeks 0, 2 and 4 (n = 5),
splenocytes were used to quantify; (A) CD4+ T cells. (B): CD8+ T cells. (C): MHC-I molecules. (D) MHC-II molecules. Data were represented as
means ± SD. The asterisk designates the significant differences (p < 0.05) between the groups. Results presented here were from three independent
experiments.
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Figure 7 Survival curves of mice in pTgDPA, pVAX1, PBS and Blank groups, following challenge with T. gondii RH strain. Survival time
was monitored daily after lethal challenge with 2 × 104 tachyzoites of virulent T. gondii RH strain, 2 weeks after the last immunization. The mice
immunized with pTgDPA were dead from day 11 to day 20, showing an increased survival time compared with mice in the control groups
(pVAX1, PBS, blanking controls), which died within 8–9 days after challenge (P < 0.05).
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cated that TgDPA induced mainly TH2 responses.
Immunoglobulins IgA, IgM and IgE were reported
to participate in the immunological responses against
T. gondii infection. However, less attention has been
placed on these immunoglobulins during vaccination
trials against T. gondii [28,29]. IgA is an important
immunoglobulin to act on neutralization of toxins and
pathogenic microbes, beside regulating interaction be-
tween specific receptors and immune mediators [30,31].
With specific relation to T. gondii infection, IgM was
reported to enhance the phagocytic capacity of neutro-
phils and activate the complement cascade which might
result in killing of T. gondii as well as reducing the spread
of T. gondii by blocking cell invasion [32-34]. In our re-
search, high titers of IgA and IgM were detected in the
immunized group. This suggested that both IgA and
IgM played roles in the protective responses induced
by the TgDPA.
IgE was recognized during the infection of toxoplas-
mosis [35,36]. However, our data revealed no significant
traces of this immunoglobulin after vaccination with
TgDPA. Our results were consistent with previous
studies [37].
IFN-γ is a key cytokine of TH1 type immune response
and is known to play an important role in resistance
against T. gondii. This cytokine supports many immuno-
logical mechanisms, interferes with survival and multi-
plication of intracellular pathogenic organisms and leads
to the eradication of pathogenic organisms [38-42]. Re-
markable levels of IFN-γ were detected in this study.
This result and the release of IgG2a isotype substantiated
the involvement of TH1 response against TgDPA. This
finding agrees with many studies in which significantproduction of IFN-γ was detected after immunization
with T. gondii antigens [25,26,43-47].
IL-4 is known as an immune regulatory cytokine of
TH2 type of immune response. In this research, the im-
munized group showed a significant release of IL-4 com-
pared to the control groups. The positive increase of this
cytokine during this investigation agrees with previous
reports highlighting the role of this cytokine during vac-
cination trials using T. gondii antigens [48,49]. The sig-
nificant release of IL-4, together with the release of IgG1
showed that the TH2 type response was involved in the
protection provided by TgDPA against the T. gondii
challenge [27,50,51].
The TH1/TH2 immune response pattern has domi-
nated the studies of cell-mediated immune resistance to
infections like toxoplasmosis [52]. Recently, a new lineage
of T helper cells recognized for producing proinflamma-
tory cytokines, such as IL-17, IL-21, and IL-22 [53], had
been identified and designated as TH17. Cytokines related
to TH17 are associated with recruitment and activation of
neutrophils during inflammatory diseases [54,55]. How-
ever, evaluation of TH17 responses during immunization
trials against T. gondii received less attention compared to
TH1 and TH2. In this investigation, after the booster
immunization, a significant increase of IL-17 concentra-
tion was detected. This finding indicated that TgDPA was
capable of inducing TH17 differentiation and resulted in
an inflammatory reaction. This result also showed that
TH17 response obviously played an important role during
immunization with TgDPA.
TGF-β is a typical cytokine of Treg cells and usually
plays inhibitory roles in the immune responses [56-59].
The inhibitory function of Treg cells was also demon-
strated during toxoplasmosis infection [60]. In this study,
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tions of TGF-β1 after the booster immunization compared
to the control groups. It indicated that immunization with
TgDPA down-regulated Treg cells response. This character
of TgDPA will be beneficial to its potential as a vaccine
candidate.
Resistance against T. gondii parasite is characterized
by the induction of specific CD4+ and CD8+ T cells,
which eventually lead to the killing of the parasite
[61,62]. In murine models, CD4+ T cells were crucial
regulators of the immune response during resistance
against toxoplasmosis, while in humans CD4+ displayed
cytotoxic activity against T. gondii infected cells [15,63,64].
On the other hand, CD8+ subtype were considered to be
the major effector cytotoxic T lymphocyte (CTL) cells
mediating lysis of T. gondii infected host cells [65-67].
In this investigation, our data demonstrated that both
cell subtypes were significantly accumulated in response
to immunization with TgDPA. This result corresponds
with reports regarding immunological responses to
T. gondii antigens [16,68-72].
In this study, results that further support the incre-
ments of both CD4+ and CD8+ T cell subsets were the
simultaneous significant increases of the ratios of MHC-I
and MHC-II. Activation of CD4+ T cells requires the
endocytosis or phagocytosis of secreted or exogenous
proteins entering into the MHC class II pathway,
while the activation of CD8+ depends on the recogni-
tion of antigens restricted by MHC class I molecules
[27,73]. The findings in this study demonstrated that
TgDPA antigen was presented through MHC-I and
MHC-II.
As a result of these significant immunological
changes, pTgDPA vaccinated mice survived for a lon-
ger time compared to the control groups in this re-
search. However, due to uncontrolled parasite replication,
pTgDPA mice ultimately succumb during late acute infec-
tion. It indicated that the DNA vaccine of pTgDPA
did not provide complete protection. However, inves-
tigations concerning this protein should further be
conducted.
One of the prominent advantages of DNA vaccine
application is their induction of CTL cells. CTL cells
kill the pathogen infected cells mainly by inducing
apoptosis [74]. T. gondii maintains its survival and
replication by interfering with infected cells apop-
tosis, blocking an important pathway known as
caspase cascade [75-78]. Measurement of damaged
infected cells was an important tool to measure CTL
function [74,79,80]. Application of such methods is
required in further investigations regarding TgDPA
antigen to highlight its role in CTL response stimu-
lation and resistance development against T. gondii
infection.Conclusion
Our study demonstrated that the pTgDPA delivered as a
single protein is an antigen with the potential of indu-
cing and regulating significant levels of humoral as well
as cellular (TH1, TH2 and TH17) immune responses
against acute T. gondii infection. This finding may en-
courage more investigations in evaluating the immuno-
genicity of DPA based vaccines against Toxoplasmosis.
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